aTyr's Efzofitimod Demonstrates Promise in Largest Sarcoidosis Trial Despite Missed Endpoint

aTyr Pharma's Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint of reducing corticosteroid dose at week 48, but secondary outcomes showed some benefits such as higher rates of steroid withdrawal and improved lung scores. The drug was well-tolerated, and the company plans to consult with the FDA to determine the next steps.